Lab Industry Says PAMA Reimbursement Rates Not Really Market-Based
Executive Summary
The US Medicare agency was supposed to peg its Clinical Lab Fee Schedule reimbursement rates for 2018 to market-based prices supplied by labs under the 2014 Protecting Access to Medicare Act. The exercise might have increased payment rates for lab tests, but clinical labs say that the new Medicare rates actually make deep cuts that could disrupt access to laboratory services.
You may also be interested in...
Medicare Allows Use Of Hospital Outreach Lab Pay Data; Industry Applauds, But Still Sues
The clinical laboratory industry praised the US Centers for Medicare and Medicaid Services for making changes in its final Clinical Laboratory Fee Schedule rule to allow more data from hospital outreach labs to be considered in setting laboratory test pay rates. But lab advocates are still pursuing a lawsuit and pushing for legislative reforms.
Lab Sector Vs. CMS Battle Heats Up As Medicare Agency Moves Forward With 2018 Rates
Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?
Remote-Monitoring Code Added, Clinical Lab Fee Payments Set In Medicare Physician Pay Schedule
US CMS added a telemedicine code, finalized payments for clinical labs, and gave more time for physicians to adapt to its Medicare appropriate-use criteria (AUC) program for advanced diagnostic imaging, as part of its recently released physician fee schedule for 2018.